StockData

Immunocore vs Twist Bioscience

IMCR and TWST side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMCR and TWST compare

Twist Bioscience is the larger company, worth 4.4 times as much as Immunocore ($6.6B against $1.5B).

Immunocore grew revenue faster over the last twelve months (21.0% versus 19.2% for Twist Bioscience).

Immunocore keeps more of each dollar of sales as profit, with a net margin of −4.2% compared with −31.7% at Twist Bioscience.

Twist Bioscience scores higher on the StockData Score (13 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMCRTWST
Size and price
Market cap$1.5B$6.6B
Share price$28.88$105.04
Change, 1 year−18.3%251%
Change, 5 years−20.6%10.6%
Beta (5Y)0.141.84
Employees524979
StockData Score
Total score713 (better)
Valuation score1 (better)0
Growth score24 (better)
Performance score33
Health score16 (better)
Dividend score00
Valuation
P/S3.5× (better)15.3×
P/B3.5× (better)14.8×
FCF yield−2.8%−1.4% (better)
Fair value$32.90$34.21
Margin of safety12.2% (better)−207%
Growth
Revenue growth (TTM)21.0% (better)19.2%
Revenue growth, 5Y average–33.1%
Profitability
Gross margin98.9% (better)52.0%
Operating margin−5.2% (better)−33.6%
Net margin−4.2% (better)−31.7%
FCF margin−9.6% (better)−21.6%
Return on equity−4.5% (better)−29.6%
Return on invested capital–−45.5%
Financial health
Debt / equity–0.00
Interest coverage−1.8×–
Current ratio4.47 (better)2.67
Altman Z-score1.4414.75 (better)
Piotroski F-score35 (better)
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%122%
Held by insiders15.5%2.2%
Insider net buying, 12 months−$1.9M (better)−$148M
Short interest, % of float–16.0%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.